References
- Ong ATL, McFadden EP, Regar E, de Jaegere PPT, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents.J. Am. Coll. Cardiol.45, 2088–2092 (2005).
- Holmes DR Jr, Leon MB, Moses JW et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis.Circulation109(5), 634–640 (2004).
- Stone GW, Ellis SG, Cox DA et al. TAXUS-IV investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.Circulation109(16), 1942–1947 (2004).
- Tanigawa J, Sutaria N, Goktekin O, Di Mario C. Treatment of unprotected left main coronary artery stenosis in the drug-eluting stent era.J. Interv. Cardiol.18(6), 455–465 (2005).
- Colombo A. Bifurcation lesions.Ital. Heart J.6(6), 475–488 (2005).
- Herz I, Moshkovitz Y, Loberman D et al. Drug-eluting stents versus bilateral internal thoracic grafting for multivessel coronary disease.Ann. Thorac. Surg.80(6), 2086–2090 (2005).
- Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn.J. Am. Coll. Cardiol.44(7), 1373–1385 (2004).
- Hausman ED, Altaie SS. Regulatory aspects of total product life cycle.Diabetes Technol. Ther.6(6), 761–766 (2004).
- Steinhubl SR, Berger PB, Mann JT III et al. CREDO investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.JAMA288, 2411–2420 (2002). Erratum:JAMA289, 987 (2003).
- Mehta SR, Yusuf S, Peters RJG et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.Lancet358, 527–533 (2001).
- von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial.Circulation112(19), 2946–2950 (2005).
- Stabile E, Cheneau E, Kinnaird T et al. Late thrombosis in Cypher stents after the discontinuation of antiplatelet therapy.Cardiovasc. Radiat. Med.5(4), 173–176 (2004).
Websites
- CYPHER sirolimus-eluting coronary stent on RAPTOR over-the-wire delivery system or RAPTORRAIL rapid exchange delivery system – P020026. FDA, MD, USA, April 24, 2003 www.fda.gov/cdrh/pdf2/p020026.html
- TAXUS Express 2 paclitaxel-eluting coronary stent system (monorail and over-the-wire) – P030025. FDA, MD, USA, March 4, 2004 www.fda.gov/cdrh/pdf3/p030025.html
- Krucoff MW. Paclitaxel elution from a bioabsorbable polymer (Conor CoStar). Oral presentation www.tctmd.com/csportal/appmanager/ tctmd/main?_nfpb=true&_pageLabel=TCTMDContent&hdCon=1278102
- Morice MC. SYNTAX: insights from the run-in phase. Oral presentation www.tctmd.com/csportal/appmanager/ tctmd/main?_nfpb=true&_pageLabel=TCTMDContent&hdCon=1256021
- O’Neill WW. Expanding PCI indications: unprotected left main stenting and distal protection. Oral presentation www.tctmd.com/csportal/appmanager/tctmd/main?_nfpb=true&_pageLabel=TCTMDContent&hdCon=1354525
- Leon MB. Thrombogenicity of DES is a growing concern. Cypher – there are no differences in stent thrombosis compared with bare metal stents. Oral presentation www.tctmd.com/csportal/appmanager/tctmd/main?_nfpb=true&_pageLabel=TCTMDContent&hdCon=1378276
- Medical Device Reporting www.fda.gov/cdrh/mdr/